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ABSTRACT V(D)J recombination substrate choice is reg-
ulated to ensure that the appropriate gene segments are
rearranged during lymphocyte development. It has been pro-
posed that regulation of substrate usage is determined by
changes in accessibility of the DNA targets. We show that
Rag-mediated recombination of an episomal substrate in cells
is affected by its packaging into chromatin. Chromatinized
substrates were inefficiently rearranged, and methylation
further reduced recombination. Disruption of nucleosomes by
using butyrate on methylated substrates was sufficient to
activate recombination, and dexamethasone could activate
recombination in the absence of detectable transcription.
Therefore, chromatin structure, and its manipulation by
altering nucleosome positioning, can directly affect recombi-
nation efficiencies.
Antigen receptor genes are assembled during lymphoid de-
velopment from gene segments flanked by recombination
signal sequences (RSSs) that are targets for the V(D)J recom-
bination machinery (1). This nonhomologous site-specific
recombination process must be precisely controlled because of
the potentially severe consequences of aberrant chromosomal
recombination events. Coexpression of the lymphoid-specific
genes Rag-1 and Rag-2 occurs in developing B and T cells,
ensuring that only the appropriate cell types are recombina-
tionally active (2). A second level of regulation exists to control
lineage specificity. Complete Ig gene rearrangement occurs
only in B cells whereas T cell receptor genes rearrange
exclusively in T cells (3). Moreover, within developing B and
T cells, there are temporal controls over antigen receptor
rearrangement. For example, in early B cells, the Ig heavy
chain is rearranged before the light chain, and D to JH gene
segments are combined before V-to-DJ assembly can com-
mence.
This remarkable ability of the recombination machinery to
target only a very small subset of substrates within a given cell,
together with the fact that a single recombinase is required for
this process, has led to the hypothesis that the accessibility of
DNA targets to the recombination machinery is tightly con-
trolled (4). Potential loci for recombination are thought to be
inaccessible until they are modified to allow the recombina-
tional machinery access to target sites. In support of this
model, forced expression of Rag-1 and Rag-2 in nonlymphoid
cells allow exogenous targets to be recombined but, the
endogenous Ig and T cell receptor gene segments within the
same cells remain unrecombined (4).
Other properties of the endogenous loci thought to be
associated with ‘‘open’’ DNA also correlate with recombina-
tional activity. These properties include transcriptional activity
and hypomethylation (5, 6). For example, transcription ini-
tiates within each locus to be rearranged at the time when
recombination commences within that region of the genome.
Extensive studies of transgenic recombination signal se-
quences have demonstrated correlative relationships between
transcriptional transactivation and recombination frequencies;
in general, transcriptionally silent transgenic substrates were
refractory to recombination (7). However, certain transgenic
substrates that were transcriptionally active were recombina-
tionally silent, suggesting that transcription itself is not suffi-
cient to render a locus recombinationally accessible and that a
mechanistic relationship, if any, between these properties is
complex (8, 9). Hypermethylation has been correlated with the
existence of a repressed state, refractory to V(D)J recombi-
nation (5, 10). Antigen receptor loci become demethylated as
they are rendered recombinationally active (11, 12). A trans-
genic model system was able to recapitulate the dependence on
hypomethylation for recombination, suggesting that changes in
CpG methylation may be another potentially important switch
for Rag-mediated recombinational accessibility (13). Because
these experiments have been correlative in nature, we felt that
an experiment that could directly test whether these properties
affected recombination efficiencies was needed.
Specifically, we wanted to determine whether DNA pack-
aging is sufficient to silence recombination loci and whether
the modulation of transcriptional activity and methylation
status can explain differences in the utilization of recombina-
tion sites in vivo. Given the size and complexity of the antigen
receptor loci, it is difficult to directly manipulate these prop-
erties to determine whether they are responsible for the
different recombination events observed. Therefore, we de-
vised a strategy that uses an episomal recombination substrate
in which we could alter the nucleosomal structure and posi-
tioning, methylation status, and transcriptional activity of
target sites within a recombination substrate to explore
whether these properties directly influence substrate targeting
by the V(D)J recombinase.
MATERIALS AND METHODS
Plasmids. pSC1 was constructed as follows. First, the RSV
promoter was deleted from pREP4 (Invitrogen), and the
Ebna1 cassette was inactivated by the insertion of a 50-bp
fragment to generate pEP4. Then, a fragment containing the
luciferase gene from pMAMneoluc (CLONTECH) was sub-
cloned into the MCS of pEP4, to generate pEL. The 23RSS
along with two flanking nucleotides 59-TGCACAGTGGTAG-
TACTCCACTGTCTGGCTGTACAAAAAC C-39 was sub-
cloned as an oligonucleotide fragment into the 39 untranslated
region of the luciferase gene in pEL, generating pEL23 (RSS
in bold face, f lanking nucleotides italicized). The mouse
mammary tumor virus long terminal repeat (MMTVLTR) was
first subcloned into pBSKS1 (NEB, Beverly, MA) and was
used as a substrate for site-directed mutagenesis by using
Epicurian Coli XLmutS Kanr Competent Cells (Stratagene) to
embed the 12 RSS 59-tgCACAGTGagtggtttcctgacAAAAA-
CA-39 (endogenous sequence in lowercase, RSS in bold).
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Subsequently, the MMTVLTR12RSS was subcloned into
pEL23, to generate pSC1. Expression vectors for full-length
murine Rag-1 and Rag-2, murine glucocorticoid receptor, and
adenovirus E1a have been described elsewhere (14–16). In
vitro methylation of plasmids were performed by using SssI
methylase according to the manufacturer (NEB).
Cell lines and Transfections. The human embryonic kidney
epithelial cell line, 293, and its derivative stably expressing
Ebna-1, 293Ebna1 (Invitrogen), were maintained in DMEM
containing 10% fetal bovine serum and PenyStrep. The human
osteosarcoma cell line, U2OS, was maintained in DMEM
containing 15% fetal bovine serum and PenyStrep. Dexameth-
asone (Sigma) was added at 1 uM, and butyrate (Sigma) was
added at 7 mM 24 hours posttransfection.
DNA was introduced into cells by calcium phosphate-
mediated transfection as described (16). Recombination sub-
strate vectors (1 mg) and other vectors (5 mg) were transfected
into cells plated 16 hr earlier. The cells were fed 24 hours
posttransfection. Cells were either harvested 48 hours post-
transfection or were selected in hygromycin (Calbiochem) to
generate stable cell lines. For analysis, the cell suspension was
divided, was washed in PBS, and was lysed for recovery of
episomal DNA (16) and in parallel for luciferase activity by
using a Promega kit according to the manufacturers’ protocol.
Background luciferase activity was subtracted from the exper-
imental samples before fold values were calculated.
Recombination Assay. One percent of the recovered DNA
was subject to PCR amplification. These PCR primers are
unable to amplify a product until the V(D)J recombination
reaction has occurred, bringing the primer sites in close
proximity. The following oligonucleotides were used to direct
the amplification of these signal-joint products: KasI, 59-
CTCTTCGGGCGCCAGCTG CCGCAG-39, SspI, 59-TGTG-
GAACGAAG TACCGAAAGGTCTTACC-39. A 50-ml PCR
amplification reaction mixture contained 10 mM TriszHCl (pH
8.3), 50 mM KCl, 2 mM MgCl2, 100 ng of each oligo, and 1 unit
of Taq polymerase (Boehringer Mannheim) and was subject to
the following amplification profile: 1 cycle of 94°C for 4 min;
(30 cycles for stable lines, and 25 cycles for transients) of 94°C
for 1 min, 72°C for 2 min; 72°C for 4 min. The products were
resolved on a 1.5% TBE (45 mM TriszBoratey1 mM EDTA,
pH 8.0) gel, were transferred to Hybond N (Amersham
Pharmacia), and were probed with the kinased oligonucleotide
SJ1 (59-GTGGAGTACTACGAGTGTGCACAGTGAGTG-
GTTTCCTG-39) that spans the newly created signal-joint. To
determine relative activities, a dilution curve for the PCR
amplification was generated for each experiment: The sample
representing pSC1 plus RAG1y2 was serially diluted into the
negative control, and the dilution series was amplified in
parallel with the control and experimental samples. Values for
band intensities of the radiolabeled PCR products were de-
termined by digitizing and quantitating using MACBAS software
(Fuji) for Fig. 1B and by PhosphorImaging (Molecular Dy-
namics) for Fig. 1D. pSC1 plus RAG1y2 was set as 1.0, and
pSC1 without RAG1y2 set as 0. Within the range of our assay,
band intensities decreased proportionally to the dilution of the
pSC1 plus RAG1y2 sample.
Ligation-Mediated (LM) PCR Assay. The LM-PCR assay
was adapted from Zhu and Roth (17). In brief, 10% of the
DNA recovered as in ref. 16 was ligated to 100 pmol prean-
nealed BW-1yBW-2 (18) by using 4 units of T4 DNA ligase
(NEB) and the supplied buffer in 100 ml at 14°C overnight. Ten
micrograms of tRNA was added before phenolychloroform
extraction and ethanol precipitation. The ligations were re-
suspended in 10 ml of TE21 (10 mM Trisy1 mM EDTA, pH
8.0), and 10% was used for PCR analysis. BW-1H (18) and
KasI (above) were used in a 50-ml PCR reaction that contained
10 mM TriszHCl (pH 8.3), 50 mM KCl, 2 mM MgCl2, 25 pmol
of each oligo, and 1 unit of Taq polymerase (Boehringer
Mannheim). The amplification profile was 1 cycle of 94°C for
4 min; 30 cycles of 94°C for 15 sec, 65°C for 30 sec, 72°C for
40 sec, and 72°C for 4 min. The products were resolved on a
1.5% TBE gel, were transferred to Hybond-N nylon (Amer-
sham Pharmacia), and were hybridized to a kinased internal
oligo KasII (59-GGCCGACCTGAGGGTCGCCGGG-39).
Bands were visualized by autoradiography. Titration curves
were run in parallel to determine the linearity of the assay.
Micrococcal Nuclease (MNase) Digestion. Nuclei were iso-
lated and digested in the presence or absence of butyrate
treatment with the indicated amounts of MNase as described
(19) except that the nuclei were resuspended in restriction
enzyme buffer supplemented with 1 mM CaCl2 for 5 min at
30°C with the number of units indicated. Genomic DNA was
purified, digested with HindIII, and run on a 1.75% TBE gel
and was Southern blotted by using random primed fragment
(2298 to 1104) of the MMTV LTR.
Protein Analysis. Rag proteins were detected as described
(16) by using anti-Rag-1 or anti-Rag-2 (PharMingen). Other
proteins were detected by isolating total cell extracts and
performing Western blot analysis using anti-human glucocor-
ticoid receptor (Affinity Bioreagents, Golden, CO) followed
by horseradish peroxidase-conjugated secondary antibodies
(Amersham Pharmacia) and were developed by using en-
hanced chemiluminescence (Sigma).
RESULTS
The recombination substrate (pSC1) contained two RSSs, one
with a 12-bp spacer (12 RSS) and another with a 23-bp spacer
(23 RSS); these are the only DNA elements required for V(D)J
recombination (ref. 20; Fig. 1A). To generate a recombination
substrate on which we could control DNA access, we embed-
ded the 12 RSS in an inducible promoter, the mouse mammary
tumor virus long terminal repeat (MMTV LTR). It adopts a
nucleosomal structure when stably maintained (21, 22).
These nucleosomes prevent access of most transcription
factors and DNA binding proteins to their cognate sites
within the promoter (23). The substrate plasmid pSC1 also
contained the Epstein–Barr virus origin of replication; by
introducing pSC1 into 293 cells that either express EBNA1
or not, we could control whether the episome could be
maintained and replicated (24). Importantly, these are low-
copy nuclear episomes that are replicated only once during
S phase, and, therefore, there is no increase in their copy
number once stably maintained (25). These properties allow
Epstein–Barr virus-based episomal vectors to adopt many of
the characteristics of stably integrated DNA, such as the
chromatin structure of the HIV LTR and the enhancer
dependence of the myc promoter (26, 27).
When stably maintained and replicated, the episome be-
comes chromatinized and transcription is inhibited by the
nucleosomal structure of the MMTV LTR. This nucleosomal
repression can be alleviated by treatment with the glucocor-
ticoid dexamethasone. Glucocorticoid receptor binding to the
promoter disrupts the nucleosomal organization, thereby al-
tering the chromatin structure and allowing additional factors
(e.g., p300) to assemble on the promoter and thus promoting
transcription (23, 28, 29). p300 is a transcriptional coactivator
required for steroid receptor-dependent transcriptional trans-
activation (30). However, whether the histone acetylase activ-
ity of p300 is required for this transactivation is unknown. The
nucleosome remodeling event mediated by nuclear hormone
receptors can be uncoupled from transcriptional transactiva-
tion if transcription factor assembly on the promoter is pre-
vented (30–32). E1a is a factor known to inactivate p300 and
is present in the 293 cells we are using for our studies (33–35).
Therefore, by preventing p300 access to the promoter we
should be able to uncouple nucleosome remodeling by glu-
cocorticoid receptors from transcriptional transactivation.
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This should allow us to examine whether alteration of nucleo-
somes alone is sufficient to activate recombination.
We also used the histone deacetylase inhibitor butyrate to
disrupt nucleosomes more globally through an increase in the
acetylation status of nucleosomes. Butyrate treatment also has
been shown to activate the MMTV LTR and other steroid-
responsive promoters (36, 37). As a monitor of transcription,
the MMTV LTR of pSC1 drives the expression of a reporter
gene, luciferase. The 23 RSS is downstream of this luciferase
gene.
V(D)J recombination was induced by either transfecting
cells containing the recombination substrate with expression
vectors for Rag-1 and Rag-2 or by cotransfecting both the
substrate and the Rag expression vectors. Rearrangement was
monitored by using an assay that specifically amplifies the
signal joint product of the recombination reaction (Fig. 1 A).
To determine whether recombination is sensitive to differ-
ences in chromatin packaging of target sites, we first compared
the efficiency of recombination of transiently introduced sub-
strates to stably maintained substrates. We also treated the
cells with either dexamethasone or butyrate to examine
whether these treatments affected the efficiency of recombi-
nation. Because transiently transfected pSC1 introduced into
cells lacking EBNA1 does not replicate, these DNA templates
do not adopt phased nucleosomes or other repressive chro-
matin structures (ref. 21; also see below). We would expect that
the recombination efficiency of these substrates should be high
and unaffected by treatments that alter nucleosomal structure.
As predicted, recombination of transiently introduced sub-
strates was unaffected by treatment with dexamethasone or
butyrate (Fig. 1B, compare lanes 2–4). The efficiency of
recombination measured by PCR on the transiently introduced
pSC1 was comparable to that of nonreplicating polyoma-based
vectors—such as pJH200 deleted for the SV40 origin of
replication—which were used in previous studies (data not
shown).
In contrast to the transiently introduced substrates, cell lines
expressing EBNA1 stably maintained pSC1, and the level of
recombination per substrate was reduced .100-fold (Fig. 1C).
Quantitation was based on titration of the transiently trans-
fected samples diluted into untransfected cell lysate and
amplified in parallel with samples generated from stable cell
lines. Additionally, Southern blot analysis of total DNA iso-
lated from purified nuclei showed a similar total episomal
content in cells that either stably or transiently maintained
pSC1 (see Fig. 3, compare lanes 1 and 7). Moreover, given that
the efficiency of transfection of 293 cells is .80% (data not
shown), the majority of cells under either condition receive the
Rag genes and the substrate vector, allowing us to compare
these conditions. Butyrate increased recombination of stable
pSC1 3-fold (Fig. 1D, compare lanes 2 and 3), a subtle but
reproducible increase. This activation of recombination was
not seen with dexamethasone, which produced a ,2-fold
effect. Southern blot analysis of total DNA recovered showed
,2-fold variability between samples (data not shown). There-
fore, we conclude that replication of this recombination sub-
strate leads to a recombinationally inhibited state that is only
marginally affected by drug treatments.
FIG. 1. Recombination efficiency is affected by the chromatin structure of the substrate. (A) Recombination substrate pSC1 contained a 12
RSS (black triangle) embedded in the MMTV LTR. The 23 RSS (white triangle) is downstream of the luciferase reporter gene. The Epstein–Barr
origin of replication (Orip) is included to allow plasmid maintenance. After V(D)J recombination, signal-joint products could be amplified by PCR
(arrows) and detected in a Southern blot probed with an oligonucleotide that spanned the newly formed signal joint (rectangle). The other product
of the recombination reaction (the coding joint) is shown but not assayed. (B) Drug treatment does not increase the efficiency of recombination
of transiently introduced substrates. pSC1 (lanes 1–4) or methylated pSC1, pSC1 ME (lanes 6–9) were cotransfected with Rag-1 and Rag-2 expression
vectors (RAG1y2) into 293 cells, and the drugs butyrate (But) or dexamethasone (Dex) were added as indicated. Assays were performed as described
in A. Fourfold less pSC1 DNA than in lanes 1–4 was transfected to generate lane 5. Relative activities were determined by using the titration series
in which transient pSC1 plus RAG1y2 was defined as 1. (C) Stably maintained episomes are inhibited by ’100-fold. Tenfold dilutions of transiently
transfected pSC1 and RAG1y2 extract into empty extract generates a titration curve (lanes 1–4). Stably maintained pSC1 cells transfected with
RAG1y2 (lane 6) or without RAG1y2 (lane 5) were amplified in parallel. (D) Stably maintained substrates are refractory to recombination, and
methylation further decreases the efficiency of recombination. Cell lines stably maintaining pSC1 (lanes 1–4) or methylated pSC1, pSC1 ME (lanes
7–10) were transfected with RAG1y2 vectors and were treated with drugs as indicated. Note: the absolute amount of recombination in D, lane
2 is ’100-fold less than in B, lane 2. Relative activities were calculated as in B except stable pSC1 plus RAG1y2 was defined as 1. (E) The levels
of Rag proteins are unaffected by drug treatments. Expression vectors for Rag-1 and Rag-2 were cotransfected into 293 cells and were treated with
dexamethasone or butyrate as indicated. Bands labeled control hybridized nonspecifically with the immunodetection reagents used.
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The recombinationally inhibited state of stable pSC1 led us
to examine whether CpG methylation of the episome would
augment the inhibition, perhaps by creating a more hetero-
chromatin-like structure. We therefore methylated pSC1 at
CpG sites in vitro to generate pSC1 ME by using SssI meth-
ylase. When transiently transfected, pSC1 ME was unaffected
by drug treatment, consistent with the lack of a nucleosomal
structure under these conditions (Fig. 1B, lanes 7–9), and the
absolute amount of recombination was similar between the
unmethylated and methylated templates, consistent with the
lack of inhibition by methylation in the absence of chromatin
assembly.
In contrast, stably maintained pSC1 ME was more refrac-
tory to recombination than pSC1 (100-fold) (Fig. 1D, compare
lanes 8 and 2). Moreover, the addition of butyrate activated
recombination 50-fold (Fig. 1D, lanes 8 and 9), almost to the
basal level of the stable, unmethylated substrate. HC toxin, a
more specific histone deacetylase inhibitor, also was used and
generated results similar to those with butyrate treatment
(data not shown). Methylation-sensitive restriction enzymes
were used to verify the maintenance of the introduced meth-
ylation status of the episomes, and that drug treatment did not
affect the introduced methylation status (data not shown).
Dexamethasone treatment also activated recombination from
this highly repressed state (9-fold) (Fig. 1D, lane 8 vs. lane 10),
although to a lesser extent than butyrate. These effects were
not attributable to changes in Rag protein levels as determined
by Western blot analysis (Fig. 1E, compare lanes 2–4). Thus,
we generated a highly repressed recombination substrate that
was derepressed by drug treatments known to modify nucleo-
somal structures.
Rag proteins initiate recombination by generating RSS-
dependent double-stranded breaks that are processed by the
ubiquitous double-strand break repair machinery (2). To
determine whether the chromatin-induced inhibition of re-
combination was attributable to a decrease in the accessibility
of the Rag proteins to the substrates or instead to an altered
efficiency of double-strand break repair, we assayed for Rag-
mediated double-strand breaks (38). LM-PCR was used to
quantify these double-strand breaks (Fig. 2A), and titration
analysis was performed to demonstrate the linearity of the
assay (Fig. 2B, lanes 9–12). The stably maintained methylated
substrates were inhibited in their ability to be cleaved by the
recombination machinery in the absence of drugs compared
with their unmethylated counterparts (Fig. 2B, compare lane
2 to lane 6). Drug treatment could substantially activate
recombination on the stably maintained methylated episomes
(Fig. 2B, lanes 6–8). Because the inhibition of recombination
product formation (Fig. 1D) by chromatin structure was
mirrored in the LM-PCR assay, the repression of recombina-
tion is at an early step in recombination, presumably the
recognition of the RSSs by the Rag proteins or, less likely, the
cleavage step itself.
To determine directly whether butyrate treatment was hav-
ing the predicted effects on the chromatin structure of pSC1,
we assayed for nuclease sensitivity under different conditions.
Previous studies have shown that, after replication, the MMTV
LTR and other steroid-responsive promoters are packaged
into a nucleosomal array that can be disrupted by butyrate
treatment (22, 36, 37). We treated nuclei containing the
episomes with MNase, an enzyme that digests the linker DNA
between nucleosomes, allowing the position and spacing of
nucleosomes on a template to be determined. The digested
DNA then was probed for MMTV LTR sequences. When
stably maintained, the MNase digestion pattern of the MMTV
LTR showed the typical ladder of positioned nucleosomes
(Fig. 3, lane 9). The ladder was not detectable when the
templates were transiently transfected, consistent with these
episomes not being packaged into nucleosomes (Fig. 3, lane 3).
A decrease in the intensity of the full length band (’6 kb) as
the amount of MNase was increased on the transient samples
(Fig. 3, lanes 1–3) indicated that the episomes were accessible
to the nuclease. Additionally, the regular nucleosomal array
generated on the stably maintained episomes was disrupted by
butyrate treatment, as seen by the less defined ladder (Fig. 3,
lane 12). The smallest DNA fragment of the nucleosome
ladder in Fig. 3, lane 9 (mononucleosome) was most clearly
disrupted by butyrate, as seen by the blurring of this band in
lane 12. As a control, the bulk genomic DNA was visualized by
ethidium bromide staining; treatment with MNase with or
without butyrate treatment under transient or stable condi-
tions led to a similar laddered digestion pattern (data not
shown). These data show that the stable episomes are pack-
aged into nucleosomes that are directly affected by butyrate
treatment.
To examine whether transcription of the recombination loci
correlated with recombination, we monitored the transcrip-
tional activity of the MMTV LTR under the same conditions.
Transiently transfected pSC1 should be constitutively accessi-
FIG. 2. The chromatin structure of a recombination substrate
directly affects the accessibility of the recombinase for its DNA
substrate. (A) Schematic diagram of the LM-PCR assay. DNA samples
were ligated to blunt linkers and were subjected to PCR by using a
linker primer and a second primer internal to the Rag-dependent
double-strand break (arrows) at the 12 RSS (black triangle). The
amplified products were subjected to Southern blot hybridization and
were probed with an oligonucleotide internal to the amplified product
(rectangle). (B) Measurement of double-strand break formation. Cell
lines stably maintaining pSC1 or pSC1 ME were cotransfected with
Rag expression vectors and were treated with drugs as indicated (lanes
1–8). Titration analysis was performed in parallel to verify the linearity
of the assay (lanes 9–12). All samples were generated from the same
experiment and gel. Assays were performed as described in A.
FIG. 3. Stably maintained pSC1 adopts a nucleosomal structure
that can be disrupted by butyrate treatment. Nucleosome positioning
on transiently (lanes 1–6) or stably maintained (lanes 7–12) pSC1,
isolated either from untreated or butyrate-treated cells, was deter-
mined by treating purified nuclei with micrococcal nuclease (MNase,
as indicated), and digested DNA was detected by Southern blot.
Molecular weight markers are indicated on the left, and the nucleo-
somal ladder is indicated on the right.
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ble to the transcription machinery, and, in fact, the addition of
butyrate had only a modest stimulatory effect (,4 fold) (Fig.
4A). In contrast, stably maintained pSC1 was highly inducible
by butyrate (.50 fold) because the drug relieved the repres-
sion of chromatin on transcription. Treatment with butyrate on
the methylated templates could also significantly activate
transcription when they were stably maintained (.100 fold).
The absolute amount of basal transcription of stably main-
tained pSC1 ME was 3-fold lower than its unmethylated
counterpart pSC1 and ,2-fold above background levels of
luciferase activity (Fig. 4A, legend). Thus, for butyrate, stim-
ulation of both transcription and recombination was coupled.
In contrast to butyrate, the addition of dexamethasone did
not significantly activate transcription of either the transiently
or stably maintained pSC1 or pSC1 ME (2-fold or less) (Fig.
4A), despite the presence of glucocorticoid receptor in these
cells (Fig. 4B). Thus, for dexamethasone, transcription and
recombination were uncorrelated.
This lack of dexamethasone-induced transcription was likely
a consequence of adenovirus E1a in our 293 cells, as has been
previously shown for other nuclear hormone receptors (31). To
examine this for our substrate, we determined whether the
steroid-dependent transcriptional transactivation of pSC1 in
U2OS cells, which lack E1a, could be inhibited by the coex-
pression of E1a. We transfected U2OS cells with pSC1 and
either a vector expressing E1a or a control vector. Treatment
with dexamethasone activated glucocorticoid receptor-
dependent transcription of the MMTV LTR that was inhibited
by the coexpression of E1a (Fig. 4C). Therefore, the lack of
steroid-mediated transcriptional transactivation in 293 cells
can be attributed to the presence of E1a.
DISCUSSION
By taking advantage of the well characterized MMTV LTR, we
have demonstrated that the chromatinized state of target DNA
can influence accessibility to the V(D)J recombination ma-
chinery in vivo. Comparing transiently transfected, nonrepli-
cating pSC1 plasmid without nucleosomal organization to
stably maintained, nucleosome-bound pSC1, it was evident
that nucleosomes inhibited recombination .100-fold. Recent
in vitro studies also have found that nucleosomal substrates are
refractory to Rag-mediated cleavage (39). We then found that
the repression mediated by nucleosomes was relieved by
butyrate, a drug known to alter nucleosomal structures. How-
ever, the more subtle changes in chromatin introduced by
dexamethasone activation of glucocorticoid receptors did not
significantly affect recombination frequencies under these
conditions. CpG methylation of nucleosomal templates further
repressed the access of the recombinase for targets an addi-
tional 100-fold. Under these conditions, treatment with bu-
tyrate or dexamethasone, both known to alter nucleosomal
packaging, increased the recombination frequency and thus,
presumably, accessibility to the recombinase. By manipulating
chromatin structures in vivo, we were able to decrease the
accessibility of the recombination machinery for target sites by
10,000-fold. This level of inhibition may be sufficient to explain
the nearly absolute specificity of recombination substrate
choice in vivo. We were then able to alleviate the repression by
using known modifiers of chromatin structure.
The chromatinization of substrates inhibited both transcrip-
tion and recombination. However, the magnitude of inhibition
on recombination was much greater (i.e., methylation of stable
pSC1 decreased transcription by 3-fold and recombination by
100-fold). Whereas butyrate treatment alleviated both the
repression of chromatin on transcription and recombination,
dexamethasone differentially affected these processes. Ste-
roid-mediated disruption of nucleosomes activated recombi-
nation by switching the substrate from an inactive to an active
one without significant transcriptional transactivation. Al-
though we could detect a slight increase in luciferase activity
after dexamethasone treatment, the level of activation was
exceedingly low and disproportionate to the recombinational
activation (1.7-fold vs. 9-fold). Therefore, it is likely that the
activation of the recombinase is almost exclusively attributable
to the nucleosomal remodeling mediated by the glucocorticoid
receptor and not transcriptional transactivation.
These data have led us to postulate a model for the
regulation of Rag-mediated recombination by the modifica-
tions of our DNA target (Fig. 5). Transiently introduced
substrates are accessible to both the transcriptional and re-
combinational machinery (Fig. 5A) and are thus unregulated.
Activation of transcription on open substrates has no effect on
recombination efficiencies (Fig. 1B; ref. 40). Nucleosomal
packaging achieved through stable maintenance of targets,
especially when CpG methylated, inhibits both transcription
and recombination (Fig. 5B). Disruption of nucleosomes lo-
cally on the MMTV LTR by using steroid-mediated glucocor-
ticoid receptor binding activates recombination but not nec-
essarily transcription (Fig. 5C). Transcription requires the
assembly of other transcription factors and coactivators (Fig.
5D). In our system, E1a inhibited the transition from the state
in Fig. 5C to that in Fig. 5D by preventing p300 assembly on
the promoter.
That the E1a in 293 cells did not prevent the dexametha-
sone-induced increase in recombination implies that the acti-
vated glucocorticoid receptor is able to increase the accessi-
bility of the recombinase to DNA even in the absence of
significant transcriptional activation. How butyrate treatment
activates transcription in the presence of E1a is not clear;
perhaps it bypasses the requirement for specific transcription
factors and coactivators. The decreased activation of recom-
FIG. 4. Transcriptional activation does not accurately reflect ac-
cessibility of a recombination substrate. (A) Transcription of the
MMTV LTR is increased by butyrate treatment when the promoter is
stably maintained. Cells harboring transiently unmethylated (white),
stably unmethylated (gray), or stably methylated (black) pSC1 were
assayed for luciferase activity after drug treatment as indicated. The
fold activation was calculated by setting the untreated samples to one,
and the numerical values are listed above the bars. The average of
three experiments is shown. The absolute level of luciferase activity of
the untreated stable pSC1 was 1,062 6 490; stable pSC1 ME was 323 6
78; and that with no extract was 237 6 76. (B) Western blot analysis
reveals that glucocorticoid receptor (GR) is expressed in 293E cells as
compared with U2OS cells that do not express glucocorticoid receptor
and HeLa cells known to express glucocorticoid receptor (42, 43). (C)
E1a can block glucocorticoid-dependent transactivation of the MMTV
LTR. U2OS cells were transfected with glucocorticoid receptor in the
presence (black) or absence (white) of E1a and dexamethasone (Dex)
and were monitored for luciferase activity.
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bination by steroids as compared with butyrate may be attrib-
utable to the fact that dexamethasone only disrupts the
nucleosomal structure of the MMTV LTR near the 12 RSS
whereas butyrate affects chromatin more globally, altering the
chromatin structures at both the 12 RSS and 23 RSS (22).
Experiments have demonstrated that by altering one RSS to
become a better substrate for recombination, the pair of sites
is used more efficiently (41). Another possibility is that
modification of the chromatin structure is sufficient to activate
recombination but that transcriptional transactivation poten-
tiates the affect.
We have determined that chromatin inhibits recombination
in vivo and have begun to define parameters that can alleviate
this repression. It will probably require in vitro studies with
reconstituted chromatin to define the specific proteins and
structures that inhibit recombination and how these modifi-
cations can alleviate the repression.
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FIG. 5. Model of accessibility. (A) Transiently introduced recom-
bination substrate not packaged into nucleosomes is recombinationally
and transcriptionally active. (B) Stably maintained, nucleosomal tar-
gets are refractory to recombination and transcription. (C) Steroid-
dependent glucocorticoid receptor binding to the MMTV LTR dis-
rupts nucleosome activating recombination but not transcription. (D)
Disruption of the nucleosomes allows assembly of transcription factors
and coactivators, allowing transcriptional transactivation and presum-
ably recombination. E1a can block the transition from C to D by
preventing p300 assembly on the promoter.
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